Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Erlotinib and Bevacizumab in Patients With Advanced Upper Gastrointestinal Carcinomas, Refractory or Intolerable to Standard Systemic Therapy

NCT00350753 is registered in ClinicalTrials.gov with Rigshospitalet, Denmark as lead sponsor.

NCT NCT00350753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00350753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Erlotinib and Bevacizumab in Patients With Advanced Upper Gastrointestinal Carcinomas, Refractory or Intolerable to Standard Systemic Therapy
Lead sponsor
Rigshospitalet, Denmark
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2006
Completion date
June 30, 2009
Enrollment
126 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, gallbladder cancer